Numbers

Claude View

The Numbers

Biocon trades at ₹345 – a 68x P/E multiple on a business earning 6% ROCE, the lowest among Indian pharma peers who average 20%+. The stock is priced entirely for a biosimilar margin inflection that has not yet shown up in consolidated returns. The single metric that will rerate or derate this stock is biosimilar EBITDA margin: every percentage point above 28% accelerates the ROCE climb from 6% toward peer-level 15%, and every miss extends the period of value destruction.

The stock sits at ₹345 against a 52-week range of ₹291 to ₹425. The analyst consensus target is ₹380-430, with Citi at ₹360 (Sell) and Investec at ₹439 (Buy). The stock has delivered -18% over the past year, underperforming the sector significantly.

Revenue and Earnings Power

Revenue nearly quadrupled from ₹39 Bn (FY2017) to ₹153 Bn (FY2025), but operating income grew only 3.3x over the same period. The Viatris acquisition in FY2023 drove the step-change from ₹82 Bn to ₹112 Bn, but the profitability catch-up has been slower – massive depreciation (₹16.9 Bn) and interest costs (₹9.0 Bn) weigh on reported earnings. Net income in FY2025 was ₹14.3 Bn, barely above the ₹10 Bn earned in FY2019 on less than half the revenue.

Quarterly revenue shows a clear seasonal pattern: Q4 is consistently the strongest quarter (₹44.2 Bn in Q4 FY25, ₹39.2 Bn in Q4 FY24). Operating margins oscillate between 18-24%, with Q1 typically the weakest. The Q3 FY26 quarter (₹41.7 Bn revenue, 20% margin) was in line with recent trends. Notably, Q1 FY25 had an exceptionally high net income of ₹8.6 Bn driven by ₹11.7 Bn of other income (likely one-time items), masking a weak 18% operating margin.

Cash Generation – The Inflection Point

This is the most important chart in the report. Biocon was FCF-negative for six consecutive years (FY2014-FY2022) as it invested heavily in biosimilar manufacturing capacity and then absorbed the Viatris acquisition. The inflection came in FY2024 (₹10.5 Bn FCF) and accelerated in FY2025 (₹17.2 Bn FCF). Operating cash flow surged 37% YoY to ₹40.6 Bn, reflecting improving biosimilar unit economics. At ₹17.2 Bn FCF on a ₹559 Bn market cap, the FCF yield is 3.1% – thin, but it was negative two years ago.

Balance Sheet: Deleveraging in Progress

The Viatris acquisition in FY2023 doubled the balance sheet overnight – total debt jumped from ₹51.5 Bn to ₹180.2 Bn, and total assets from ₹203 Bn to ₹517 Bn. Deleveraging is underway: the ₹4,500 crore QIP in June 2025 plus structured debt retirement have pushed equity up to ₹268 Bn (H1 FY26) while debt fell to ₹165 Bn. Debt-to-equity improved from 1.01x (FY2023) to 0.62x (H1 FY26). Net debt at the Biocon Biologics level is $1.1-1.2 billion, with S&P upgrading the rating from BB to BB+ in January 2026.

Interest coverage collapsed from 26x (FY2022) to 3.3x (FY2024) post-acquisition. It has stabilized at 3.6x in FY2025. Management expects ₹300 crore annualized interest savings from FY2027 as remaining structured instruments are retired, which would push coverage above 4x.

Capital Returns: The Core Problem

This chart explains why the stock has underperformed for three years. Biocon's ROCE has been stuck at 6% since FY2023 while peers have improved to 20%+. The gap is entirely driven by the Viatris acquisition: the capital base more than doubled (total assets from ₹203 Bn to ₹557 Bn) while operating income grew just 80%. The market is paying 68x earnings for a company that currently destroys economic value (ROCE below cost of equity). The bet is that this gap closes by FY2028.

Operating Margin Architecture

Operating margins have been remarkably stable at 21-22% for five years despite the transformative acquisition. The problem is below the operating line: depreciation (₹16.9 Bn, 11% of revenue), interest (₹9.0 Bn, 6% of revenue), and tax (24% rate) compress net margins to 9%. As depreciation stabilizes and interest falls, net margins should expand toward 12-15% by FY2028 without any improvement in operating margins.

Shareholding: Promoter Dilution

Two significant shifts: (1) Promoter stake fell from 60.6% to 44.9% following the ₹4,500 crore QIP (June 2025) and the Biocon Biologics merger (which brought in new shareholders). Management stated maintaining majority stake remains strategically important. (2) DII holding nearly doubled from 12.6% to 24.1%, suggesting domestic institutional conviction is building even as FIIs remain cautious (5.7% to 7.1%). The rising DII base provides price support.

Peer Valuation: Priced for Perfection

Biocon occupies the worst quadrant: highest P/E, lowest ROCE. The only peer with a comparably high multiple is Divis Labs (64x P/E), but Divis earns 20% ROCE and runs a near-debt-free balance sheet. Biocon's valuation premium over generic peers (Dr. Reddys 18.5x, Cipla 20.6x, Lupin 21.3x) is entirely a biosimilar story. If biosimilar EBITDA margins stall below 30%, the multiple will compress toward the generic peer range of 18-22x, implying 70%+ downside.

The Biosimilar Margin Ramp – The Critical Chart

GLP-1 Optionality

Biocon secured US FDA approval for generic Saxenda (liraglutide) in early 2026 and has been launching across EU markets. The addressable market for generic liraglutide in the US is approximately $127 million (after Novo Nordisk's aggressive price cuts). Management targets high-teens to low-20% US market share within 2-3 years with limited competition. The broader GLP-1 market is projected at $101 Bn (2026) growing to $180-185 Bn by 2033-2035. However, Biocon's near-term revenue from GLP-1 remains immaterial – this is a 2027-2028 story at earliest. The real prize is generic semaglutide, where Biocon has signed distribution deals (Biomm in Brazil, Ajanta in Africa/Middle East) but US approval timelines remain unclear.

Working Capital Efficiency

The cash conversion cycle has improved dramatically from 184 days (FY2022) to 18 days (FY2025). This is driven by extending payable days to 460 (supplier financing power from scale) while reducing inventory days from 423 to 346. Debtor days at 131 remain elevated for the sector, reflecting the global biosimilar tender business model where government healthcare systems pay slowly.

EPS and Per-Share Economics

EPS in FY2025 was ₹8.44, essentially flat versus FY2024 (₹8.52) despite revenue growth. The QIP-driven dilution (equity capital rose from ₹6.0 Bn to ₹6.68 Bn in H1 FY26, roughly 11% dilution) will further pressure per-share metrics going forward. At ₹345 and ₹8.44 EPS, the stock trades at 41x trailing earnings if you adjust for the diluted share count, but the market is pricing in FY27-28 EPS of ₹12-15 to make the 68x headline P/E work on a forward basis.

What the Numbers Confirm, Contradict, and Demand

The numbers confirm three things: the FCF inflection is real and accelerating (₹17.2 Bn in FY2025 vs. negative for six prior years), biosimilar margins are expanding (28% EBITDA in Q3 FY26), and deleveraging is on track (debt-to-equity from 1.01x to 0.62x in three years).

The numbers contradict the market's implied confidence: ROCE is stuck at 6%, net margins are compressed at 9%, EPS growth is flat despite a 3.4% revenue increase, and the QIP diluted shareholders by ~11%. At 68x earnings, the stock prices in a future that requires ROCE to more than double within three years.

Watch next quarter: biosimilar EBITDA margin (does it cross 28% sustainably?), interest expense trajectory (does the ₹300 crore savings begin?), and GLP-1 revenue contribution from US Saxenda launch. If biosimilar margins reach 30% and interest drops by ₹300 crore, FY27 EPS could reach ₹12-14 – which would compress the P/E to 25-29x, within the peer range. That is the bull case in a single sentence.